JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies

Seminars in Cell and Developmental Biology

Volumn 19, Issue 4, 2008, Pages 385-393

  Vainchenker, William ^a,b,e   Dusa, Alexandra ^c,d   Constantinescu, Stefan N ^c,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d DE DUVE INSTITUTE   (Belgium)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Acute leukemia; Exon 12 JAK2 mutations; Immunodeficiency; JAK2 V617F; Janus kinases; Myeloproliferative diseases

Indexed keywords

JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PROTEIN KINASE TYK2; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ENZYME ACTIVATION; EPIGENETICS; GENE MUTATION; GENE TRANSLOCATION; GENETICS; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LEUKEMIA; MYELOPROLIFERATIVE DISORDER; OLIGOMERIZATION; PATHOPHYSIOLOGY; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; T CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA;

MAMMALIA;

EID: 52949089050     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2008.07.002     Document Type: Review

References (121)

1. Wilks A.F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA 86 5 (1989) 1603-1607
2. Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zurcher G., and Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 11 4 (1991) 2057-2065
3. Harpur A.G., Andres A.C., Ziemiecki A., Aston R.R., and Wilks A.F. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7 7 (1992) 1347-1353
4. Krolewski J.J., Lee R., Eddy R., Shows T.B., and Dalla-Favera R. Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene 5 3 (1990) 277-282
5. Velazquez L., Fellous M., Stark G.R., and Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70 2 (1992) 313-322
6. Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.Q., Lal B.K., et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci USA 91 14 (1994) 6374-6378
7. Witthuhn B.A., Silvennoinen O., Miura O., Lai K.S., Cwik C., Liu E.T., et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370 6485 (1994) 153-157
8. Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K., et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370 6485 (1994) 151-153
9. Watowich S.S., Wu H., Socolovsky M., Klingmuller U., Constantinescu S.N., and Lodish H.F. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol 12 (1996) 91-128
10. Livnah O., Stura E.A., Middleton S.A., Johnson D.L., Jolliffe L.K., and Wilson I.A. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283 5404 (1999) 987-990
11. Remy I., Wilson I.A., and Michnick S.W. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283 5404 (1999) 990-993
12. Constantinescu S.N., Keren T., Socolovsky M., Nam H., Henis Y.I., and Lodish H.F. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 98 8 (2001) 4379-4384
13. Constantinescu S.N., Huang L.J., Nam H., and Lodish H.F. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 7 2 (2001) 377-385
14. Seubert N., Royer Y., Staerk J., Kubatzky K.F., Moucadel V., Krishnakumar S., et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 12 5 (2003) 1239-1250
15. Lu X., Gross A.W., and Lodish H.F. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem 281 11 (2006) 7002-7011
16. Gent J., van Kerkhof P., Roza M., Bu G., and Strous G.J. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci USA 99 15 (2002) 9858-9863
17. Brown R.J., Adams J.J., Pelekanos R.A., Wan Y., McKinstry W.J., Palethorpe K., et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 12 9 (2005) 814-821
18. Renauld J.C. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 3 8 (2003) 667-676
19. Mullersman J.E., and Pfeffer L.M. A novel cytoplasmic homology domain in interferon receptors. Trends Biochem Sci 20 2 (1995) 55-56
20. Argetsinger L.S., Campbell G.S., Yang X., Witthuhn B.A., Silvennoinen O., Ihle J.N., et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74 2 (1993) 237-244
21. Witthuhn B.A., Quelle F.W., Silvennoinen O., Yi T., Tang B., Miura O., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74 2 (1993) 227-236
22. Muller M., Briscoe J., Laxton C., Guschin D., Ziemiecki A., Silvennoinen O., et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366 6451 (1993) 129-135
23. Watling D., Guschin D., Muller M., Silvennoinen O., Witthuhn B.A., Quelle F.W., et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 366 6451 (1993) 166-170
24. Boussiotis V.A., Barber D.L., Nakarai T., Freeman G.J., Gribben J.G., Bernstein G.M., et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 266 5187 (1994) 1039-1042
25. Russell S.M., Johnston J.A., Noguchi M., Kawamura M., Bacon C.M., Friedmann M., et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266 5187 (1994) 1042-1045
26. Ziemiecki A., Harpur A.G., and Wilks A.F. JAK protein tyrosine kinases: their role in cytokine signalling. Trends Cell Biol 4 6 (1994) 207-212
27. Leonard W.J., and O'Shea J.J. Jaks and STATs: biological implications. Annu Rev Immunol 16 (1998) 293-322
28. Gurniak C.B., Thomis D.C., and Berg L.J. Genomic structure and promoter region of the murine Janus-family tyrosine kinase Jak3. DNA Cell Biol 16 1 (1997) 85-94
29. Radtke S., Haan S., Jorissen A., Hermanns H.M., Diefenbach S., Smyczek T., et al. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem 280 27 (2005) 25760-25768
30. Girault J.A., Labesse G., Mornon J.P., and Callebaut I. Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Mol Med 4 12 (1998) 751-769
31. Huang L.J., Constantinescu S.N., and Lodish H.F. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 8 6 (2001) 1327-1338
32. Radtke S., Hermanns H.M., Haan C., Schmitz-Van De Leur H., Gascan H., Heinrich P.C., et al. Novel role for Janus kinase 1 in the regulation of oncostatin M receptor surface expression. J Biol Chem 10 (2002) 10
33. Ragimbeau J., Dondi E., Alcover A., Eid P., Uze G., and Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 22 3 (2003) 537-547
34. Royer Y., Staerk J., Costuleanu M., Courtoy P.J., and Constantinescu S.N. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem 280 29 (2005) 27251-27261
35. Lucet I.S., Fantino E., Styles M., Bamert R., Patel O., Broughton S.E., et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107 1 (2006) 176-183
36. Boggon T.J., Li Y., Manley P.W., and Eck M.J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106 3 (2005) 996-1002
37. Hubbard S.R., Wei L., Ellis L., and Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372 6508 (1994) 746-754
38. Lindauer K., Loerting T., Liedl K.R., and Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 14 1 (2001) 27-37
39. Saharinen P., and Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277 49 (2002) 47954-47963
40. Saharinen P., Vihinen M., and Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14 4 (2003) 1448-1459
41. Saharinen P., Takaluoma K., and Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 20 10 (2000) 3387-3395
42. Liu K.D., Gaffen S.L., Goldsmith M.A., and Greene W.C. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr Biol 7 11 (1997) 817-826
43. Feng J., Witthuhn B.A., Matsuda T., Kohlhuber F., Kerr I.M., and Ihle J.N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 17 5 (1997) 2497-2501
44. Gauzzi M.C., Velazquez L., McKendry R., Mogensen K.E., Fellous M., and Pellegrini S. Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J Biol Chem 271 34 (1996) 20494-20500
45. Lacronique V., Boureux A., Valle V.D., Poirel H., Quang C.T., Mauchauffe M., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278 5341 (1997) 1309-1312
46. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 2 (1994) 307-316
47. Romana S.P., Mauchauffe M., Le Coniat M., Chumakov I., Le Paslier D., Berger R., et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85 12 (1995) 3662-3670
48. Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J., Philip P., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90 7 (1997) 2535-2540
49. Nguyen M.H., Ho J.M., Beattie B.K., and Barber D.L. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J Biol Chem 276 35 (2001) 32704-32713
50. Santos S.C., Monni R., Bouchaert I., Bernard O., Gisselbrecht S., Gouilleux F., et al. Involvement of the NF-kappaB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Lett 497 2-3 (2001) 148-152
51. Malinge S., Monni R., Bernard O., and Penard-Lacronique V. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 25 25 (2006) 3589-3597
52. Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R., et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6 3 (2000) 693-704
53. Carron C., Cormier F., Janin A., Lacronique V., Giovannini M., Daniel M.T., et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95 12 (2000) 3891-3899
54. Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. Embo J 17 18 (1998) 5321-5333
55. dos Santos N.R., and Ghysdael J. A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia. Leukemia 20 1 (2006) 182-185
56. Kennedy J.A., Barabe F., Patterson B.J., Bayani J., Squire J.A., Barber D.L., et al. Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proc Natl Acad Sci USA 103 45 (2006) 16930-16935
57. Reiter A., Walz C., Watmore A., Schoch C., Blau I., Schlegelberger B., et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65 7 (2005) 2662-2667
58. Bousquet M., Quelen C., De Mas V., Duchayne E., Roquefeuil B., Delsol G., et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24 48 (2005) 7248-7252
59. Murati A., Gelsi-Boyer V., Adelaide J., Perot C., Talmant P., Giraudier S., et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 19 9 (2005) 1692-1696
60. Adelaide J., Perot C., Gelsi-Boyer V., Pautas C., Murati A., Copie-Bergman C., et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 20 3 (2006) 536-537
61. Griesinger F., Hennig H., Hillmer F., Podleschny M., Steffens R., Pies A., et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 44 3 (2005) 329-333
62. Luo H., Rose P., Barber D., Hanratty W.P., Lee S., Roberts T.M., et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 17 3 (1997) 1562-1571
63. Harrison D.A., Binari R., Nahreini T.S., Gilman M., and Perrimon N. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J 14 12 (1995) 2857-2865
64. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 7037 (2005) 1144-1148
65. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 9464 (2005) 1054-1061
66. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 4 (2005) 387-397
67. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 17 (2005) 1779-1790
68. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 11 (2006) 4274-4281
69. Lacout C., Pisani D.F., Tulliez M., Moreau Gachelin F., Vainchenker W., and Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 (2006) 1652-1660
70. Zaleskas V.M., Krause D.S., Lazarides K., Patel N., Hu Y., Li S., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1 (2006) e18
71. Campbell P.J., and Green A.R. The myeloproliferative disorders. N Engl J Med 355 23 (2006) 2452-2466
72. Szpurka H., Tiu R., Murugesan G., Aboudola S., Hsi E.D., Theil K.S., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 7 (2006) 2173-2181
73. Renneville A., Quesnel B., Charpentier A., Terriou L., Crinquette A., Lai J.L., et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 20 11 (2006) 2067-2070
74. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280 24 (2005) 22788-22792
75. Wernig G., Gonneville J.R., Crowley B.J., Rodrigues M.S., Reddy M.M., Hudon H.E., et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111 7 (2008) 3751-3759
76. Lu X., Huang L.J., and Lodish H.F. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem (2007)
77. Lu X., Levine R., Tong W., Wernig G., Pikman Y., Zarnegar S., et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 102 52 (2005) 18962-18967
78. Funakoshi-Tago M., Pelletier S., Moritake H., Parganas E., and Ihle J.N. Jak2 FERM domain interaction with the Erythropoietin Receptor regulates Jak2 kinase activity. Mol Cell Biol 28 5 (2008) 1792-1801
79. Delhommeau F., Dupont S., Tonetti C., Masse A., Godin I., Le Couedic J.P., et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109 1 (2007) 71-77
80. Jamieson C.H., Gotlib J., Durocher J.A., Chao M.P., Mariappan M.R., Lay M., et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 103 16 (2006) 6224-6229
81. Ishii T., Zhao Y., Sozer S., Shi J., Zhang W., Hoffman R., et al. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol 35 11 (2007) 1633-1640
82. Oppliger Leibundgut E., Horn M.P., Brunold C., Pfanner-Meyer B., Marti D., Hirsiger H., et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica 91 11 (2006) 1465-1472
83. James C, Mazurier F, Chaligne R, Dupont S, Delhommeau F, Giraudier S, et al. The hematopoietic stem cell compartment Is different in polycythemia vera and idiopathic myelofibrosis. Blood 2008, in press.
84. Dupont S., Masse A., James C., Teyssandier I., Lecluse Y., Larbret F., et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110 3 (2007) 1013-1021
85. Scott L.M., Scott M.A., Campbell P.J., and Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108 7 (2006) 2435-2437
86. Tiedt R., Hao-Shen H., Sobas M.A., Looser R., Dirnhofer S., Schwaller J., et al. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111 8 (2008) 3931-3940 [Abstract 674]
87. Levine R.L., Belisle C., Wadleigh M., Zahrieh D., Lee S., Chagnon P., et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107 10 (2006) 4139-4141
88. Kiladjian J.J., Elkassar N., Cassinat B., Hetet G., Giraudier S., Balitrand N., et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 20 6 (2006) 1181-1183
89. Theocharides A., Boissinot M., Girodon F., Garand R., Teo S.S., Lippert E., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110 1 (2007) 375-379
90. Campbell P.J., Baxter E.J., Beer P.A., Scott L.M., Bench A.J., Huntly B.J., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108 10 (2006) 3548-3555
91. Kim Y.K., Shin M.G., Kim H.R., Yang D.H., Cho S.H., Lee J.J., et al. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res (2007)
92. Li S., Kralovics R., De Libero G., Theocharides A., Gisslinger H., and Skoda R.C. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood (2008)
93. Bocchia M., Vannucchi A.M., Gozzetti A., Guglielmelli P., Poli G., Crupi R., et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol 8 10 (2007) 864-866
94. Sotlar K., Bache A., Stellmacher F., Bultmann B., Valent P., and Horny H.P. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis-associated clonal hematological nonmast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn 10 1 (2008) 58-66
95. Plo I., Nakadake M., Wiesmuller L., Giraudier S., Villeval J.-L., and Vainchenker W. JAK2 activation stimulates homologous recombination and genetic instability. Blood 112 4 (2008) 1402-1412
96. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 5 (2007) 459-468
97. Butcher C.M., Hahn U., To L.B., Gecz J., Wilkins E.J., Scott H.S., et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 22 4 (2008) 870-873
98. Colaizzo D., Amitrano L., Tiscia G.L., Grandone E., Guardascione M.A., and Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 110 7 (2007) 2768-2769
99. Giordanetto F., and Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 15 9 (2002) 727-737
100. Schnittger S., Bacher U., Kern W., Schroder M., Haferlach T., and Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 20 12 (2006) 2195-2197
101. Grunebach F., Bross-Bach U., Kanz L., and Brossart P. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia 20 12 (2006) 2210-2211
102. Karow A., Waller C., Reimann C., Niemeyer C.M., and Kratz C.P. JAK2 mutations other than V617F: a novel mutation and mini review. Leuk Res 32 2 (2008) 365-366
103. Zhang S.J., Li J.Y., Li W.D., Song J.H., Xu W., and Qiu H.X. The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Int J Lab Hematol 29 1 (2007) 71-72
104. Najfeld V., Cozza A., Berkofsy-Fessler W., Prchal J., and Scalise A. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 35 11 (2007) 1668-1676
105. Malinge S., Ben-Abdelali R., Settegrana C., Radford-Weiss I., Debre M., Beldjord K., et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 109 5 (2007) 2202-2204
106. Ganmore I., Bercovich D., Scott L.M., Green A.R., Cazzaniga G., Biondi A., et al. Collaboration between activating mutations in JAK2 and trisomy 21 in the acute lymphoblastic leukemias of down syndrome (DS). Blood 110 (2007) [ASH Abstract 6]
107. Walters D.K., Mercher T., Gu T.L., O'Hare T., Tyner J.W., Loriaux M., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10 1 (2006) 65-75
108. Kratz C.P., Boll S., Kontny U., Schrappe M., Niemeyer C.M., and Stanulla M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 20 2 (2006) 381-383
109. Lee J.W., Kim Y.G., Soung Y.H., Han K.J., Kim S.Y., Rhim H.S., et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25 9 (2006) 1434-1436
110. Mercher T., Wernig G., Moore S.A., Levine R.L., Gu T.L., Frohling S., et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108 8 (2006) 2770-2779
111. Staerk J., Kallin A., Demoulin J.B., Vainchenker W., and Constantinescu S.N. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 280 51 (2005) 41893-41899
112. Xiang Z., Zhao Y., Mitaksov V., Fremont D.H., Kasai Y., Molitoris A., et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 111 9 (2008) 4809-4812
113. Flex E., Petrangeli V., Stella L., Chiaretti L., Hornakova T., Knoops L., et al. Somatically aquired JAK1 mutations in acute lymphoblastic leukemia. J Exp Med 205 4 (2008) 751-758
114. Candotti F., Oakes S.A., Johnston J.A., Giliani S., Schumacher R.F., Mella P., et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 90 10 (1997) 3996-4003
115. O'Shea J.J., Husa M., Li D., Hofmann S.R., Watford W., Roberts J.L., et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 41 6-7 (2004) 727-737
116. Matthews D.J., Clark P.A., Herbert J., Morgan G., Armitage R.J., Kinnon C., et al. Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15. Blood 85 1 (1995) 38-42
117. Cacalano N.A., Migone T.S., Bazan F., Hanson E.P., Chen M., Candotti F., et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J 18 6 (1999) 1549-1558
118. Hofmann S.R., Lam A.Q., Frank S., Zhou Y.J., Ramos H.L., Kanno Y., et al. Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited. Mol Cell Biol 24 11 (2004) 5039-5049
119. Minegishi Y., Saito M., Morio T., Watanabe K., Agematsu K., Tsuchiya S., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 5 (2006) 745-755
120. Watford W.T., and O'Shea J.J. Human tyk2 kinase deficiency: another primary immunodeficiency syndrome. Immunity 25 5 (2006) 695-697
121. Fischer P., Lehmann U., Sobota R.M., Schmitz J., Niemand C., Linnemann S., et al. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J 378 Pt 2 (2004) 449-460